antiviral news

Press Releases in the global landscape
Feb 4, 2025

Why SARS-CoV-2 bounces back after antiviral treatment

The antiviral combination of nirmatrelvir and ritonavir (brand name Paxlovid) is an effective treatment for people with COVID-19 who have mild symptoms and face a high risk of hospitalization. For some of those people, however, the virus returns, and those patients may experience more symptoms and spread the virus to others.
Read More »
Jan 24, 2025

Shionogi signs contract with Taiwan government to supply 'Xocova' for reserves

On the 22nd, Shionogi Pharmaceutical of Japan announced that it signed a contract with the Taiwanese government to supply the COVID-19 treatment 'Xocova' to Taiwan for stockpiling. Shionogi will receive up to 1 billion yen for a contract of approximately 2 years and will strengthen its business in overseas markets by establishing Xocova as one of its main products in Japan. On the same day, Shionogi announced that it had also received an application for approval of Xocova in Taiwan.
Read More »
Jan 22, 2025

Electroacupuncture may aid in personalized ribavirin dosing for long COVID

Various devices are used to study the unique electrical properties of acupuncture points (APs), with Voll's electropuncture diagnostics (EAV) occupying a prominent role.
Read More »
Jan 21, 2025

Azvudine beats paxlovid in reducing COVID-19 deaths

In hospitalized COVID-19 patients, azvudine shows lower all-cause mortality and fewer adverse events than Paxlovid, with added antitumor effects observed.
Read More »
Jan 21, 2025

US HHS awards Shionogi $375M to develop COVID-19 PrEP therapy

Shionogi & Co. Ltd. won a $375 million project agreement from the Rapid Response Partnership Vehicle to develop its 3CL protease inhibitor, S-892216, as a long-acting injectable for COVID-19 pre-exposure prophylaxis.
Read More »
Jan 21, 2025

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Model Medicines, a pioneering biotech company focused on developing first-in-class therapeutics addressing urgent global health challenges, today announced the release of its latest scientific pre-print, titled "MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases". This landmark study highlights the development of MDL-001, a first-in-class, oral, broad spectrum antiviral therapy with efficacy against multiple viral pathogens of pandemic potential. The company was recently named one of the "Ten Companies to Watch in AI Drug Discovery" by Genetic Engineering and Biotechnology News, where it was featured alongside Recursion Pharmaceuticals, Schrödinger, Relay Therapeutics, Insilico Medicine, and Generate Biomedicines.
Read More »